[Federal Register Volume 64, Number 171 (Friday, September 3, 1999)]
[Notices]
[Pages 48401-48402]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-22986]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[INFO-99-33]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call the CDC Reports
Clearance Officer on (404) 639-7090.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques for other
forms of information technology. Send comments to Seleda Perryman, CDC
Assistant Reports Clearance Officer, 1600 Clifton Road, MS-D24,
Atlanta, GA 30333. Written comments should be received within 60 days
of this notice.
Proposed Project
1. Interstate shipment of etiologic agents are regulated by 42 CFR
part 7. This rule establishes minimal packaging requirements for all
viable microorganisms, illustrates the appropriate shipping label, and
provides reporting instructions regarding damaged packages and failure
to receive a shipment. In recent years the threat of illegitimate use
of infectious agents has attracted increasing interest from the
perspective of public health. CDC is concerned about the possibility
that the interstate transportation of certain infectious agents could
have adverse consequences for human health and safety. CDC has already
requested that all those entities that ship dangerous human infectious
agents exercise increased vigilance prior to shipment to minimize the
risk of illicit access to infectious agents. Of special concern are
pathogens and toxins causing anthrax, botulism brucellosis, plague, Q
fever, tularemia, and all agents classified for work at Biosafety Level
4. This information collection ensures that selected infectious agents
are not shipped to parties ill-equipped to handle them appropriately,
or who do not have legitimate reasons to use them and to implement a
system whereby scientists and researchers involved in legitimate
research may continue transferring and receiving these agents without
undue burdens. Respondents include laboratory facilities such as those
operated by government agencies, universities, research institutions,
and commercial entities. This request is for the information collection
requirements contained in 42 CFR 71.54, 72.3(e) and 72.4 relating to
the importation and shipment of etiologic agents. The complete request
for clearance is currently under development at CDC and this request
for a 6-month extension will ensure that data collection activities
remain in effect through the clearance process. The total maximum cost
to respondents is $1,000,000.
----------------------------------------------------------------------------------------------------------------
Number of Average burden/
CFR section Number of responses/ responses (in Total burden
respondents respondents hrs.) (in hrs.)
----------------------------------------------------------------------------------------------------------------
Application for Permit.......................... 1,000 1 20/60 333
72.3(3)......................................... 50 1 3/60 3
72.4............................................ 2 1 3/60 1
72.6 (a)........................................ 1,000 1 15/60 250
72.6 (d)........................................ 1,000 3 30/60 1,500
72.6 (e)........................................ 120 21 10/60 420
72.6 (f)........................................ 1,000 3 8/60 400
---------------
Total....................................... .............. .............. .............. 2,907
----------------------------------------------------------------------------------------------------------------
[[Page 48402]]
Dated: August 30, 1999.
Nancy Cheal,
Acting Associate Director for Policy Planning and Evaluation, Centers
for Disease Control and Prevention.
[FR Doc. 99-22986 Filed 9-2-99; 8:45 am]
BILLING CODE 4163-18-P
